Signal‐Transduction Therapy: A Novel Approach to Disease Management

European Journal of Biochemistry

Volumn 226, Issue 1, 1994, Pages 1-13

  Levitzki, Alexander ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 DI TERT BUTYL ALPHA CYANO 4 HYDROXYTHIOCINNAMAMIDE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; ANTIESTROGEN; BZA 4; CYCLOSPORIN A; FULVESTRANT; L 731734; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RAS PROTEIN; TACROLIMUS; TAMOXIFEN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CANCER; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ARTERIOSCLEROSIS; CALCIUM; COMBINED MODALITY THERAPY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSION; ISOENZYMES; NEOPLASMS; PHOSPHOLIPASE C; PHOSPHOLIPASE D; PROTEIN KINASE C; PROTEIN-TYROSINE KINASE; PSORIASIS; RAS PROTEINS; RECEPTORS, STEROID; SHOCK, SEPTIC; SIGNAL TRANSDUCTION;

EID: 0028000069     PISSN: 00142956     EISSN: 14321033     Source Type: Journal    
DOI: 10.1111/j.1432-1033.1994.tb20020.x     Document Type: Review

References (122)

1. Selective interactions of transforming and normal abl proteins with ATP, tyrosine copolymer substrates and tyrphostins
2. bcr‐abl tyrosine kinase activity induces K562 to differentiate
3. Differential inhibition of the epidermal growth‐factor, platelet derived growth and protein kinase C mediated signal‐transduction pathways by the staurosporine derivative CGP 41251
4. Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet‐derived growth‐factor (PDGF) and PDGF receptor mRNAs and their protein products
5. Leflunomide (HWA486) a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection
6. Sensitization of human cervical carcinoma cells to cis‐diamminedichloroplatinum (II) by bryostatin 1
7. The potential of protein kinase C for anticancer treatment
8. Membrane interactive lipid as experimental anticancer drugs
9. Antitumor effects of doxorubicin in combination with anti‐EGF receptor monoclonal antibodies
10. Efficient reversion of simian sarcoma virus‐transformation and inhibition of growth‐factors induced mitogenesis by suramin
11. Molecular themes in oncogenesis
12. Ras oncogenes in human cancer: a review
13. Demethoxyviridin and wortmannin block phospholipase C at D activation in the human neutrophil
14. A 4‐hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780
15. 4,5‐Dianilinophathalimide: a protein‐tyrosine kinase inhibitor with selectivity for the epidermal growth‐factor receptor signal‐transduction pathway and potent in vivo antitumor activity
16. Arylamides of hydroxylated isoquinolines as protein‐tyrosine kinase inhibitors
17. Calcium mediated signal‐transduction: biology, biochemistry and therapy
18. The antiestrogen ICI 182,780 disrupts estrogen receptor nucleocytoplasmic shuttling
19. Investigation of a new antiestrogen (ICI 182 780) in women with primary breast cancer
20. Tyrosine kinase‐nuclear proto‐oncogene interactions in breast Cancer
21. Induction of apoptosis. New targets for cancer chemotherapy
22. Down modulation of an oncogenic protein product and reversion of the transformed phenotype by monoclonal antibodies
23. Inhibition of tumor growth by monoclonal antibody reactive with an oncogene encoded tumor antigen
24. Steroid hormone agonists and antagonists in the treatment of cancer
25. Tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors
26. Suramin, an active drug for prostate cancer: interim observations in a phase 1 clinical trial
27. Antitumor effect of anti‐EGF receptor monoclonal antibody plus cis ‐diaminodichloroplatinum as well established A431 cell xenografts
28. Genetic model for colorectal tumorgenesis
29. The antiproliferative and antimetastatic compound LG53582 inhibits muscarinic acetylcholine receptor stimulated calcium influx and arachidonic acid release
30. Tumor‐suppressor function of muscarinic acetylcholine receptors is associated with activation of receptor‐operated calcium influx
31. Tamoxifen enhances the cytotoxic effects of the nitrosouzea folemustine. Results in human melanoma lines
32. 2+ in phosphatidylcholine breakdown
33. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells
34. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors
35. Tyrphostins II: heterocyclic and α‐substituted benzonemaloronitrile tyrphostins as potent inhibitors of EGF Receptor and ErbB2/neu tyrosine kinases
36. Tyrphostin 3. Structure‐activity relationship studies of α‐substituted benzylidenemalononitrile 5‐S‐aryltyrphostins
37. Platelet‐derived growth‐factor and proliferative glomerulonephritis
38. Inhibition of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors
39. Protein kinase C modulation
40. Monoclonal antibodies directed to the erbB‐2 receptor inhibit in vivo tumor cell growth
41. The growth regulation of keratinocytes
42. Proline isomerases at the crossroads of protein folding, signal‐transduction and immunosuppression
43. Platelet‐derived growth‐factor and its receptor in human glioma tissue. Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops
44. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity
45. Circumvention of tamoxifen resistance by the pure antiestrogen ICI 182,780
46. Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells
47. A dominant negative mutation suppresses the function of normal EGF receptors by heterodimerization
48. bcr‐abl tyrosine autokinase activity in K562 chronic myelogenous leukemia
49. Her‐2 antibody
50. Calphostin C (UCN 1028c) a novel microbial compound is highly potent and specific inhibitor of protein kinase C
51. Selective inhibition of ras‐dependent transformation by a farnesyltransferase inhibitor
52. Structure‐function analysis of signal and growth inhibition by carboxyamido‐riazole, CAI
53. L651582 a novel antiproliferative and antimetastasis agent
54. In vivo efficacy of a novel inhibitor of selected signal‐transduction pathways including calcium, arachidonate, and inositol phosphates
55. Overexpression of the epidermal growth‐factor receptor in human pancreatic cancer is associated with concomitant increase in the level of epidermal growth‐factor and TGFα
56. Selective PDGF receptor kinase blockers reverse sis‐transformation
57. Amplification of PDGFR, a gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin
58. Suramin – an anticancer drug with unique biological effects
59. Reversal of transformed phenotypes by antisense fos
60. Intracellular retention of membrane‐anchored v‐sis protein abrogates autocrine signal‐transduction
61. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal‐transduction
62. Differential responses of human tumor cell lines to anti‐p185Her‐2 monoclonal antibodies
63. Potentiation of 1‐β‐d‐arabinofuranosylacytosine by the protein kinase C activator bryostatin 1 in HL‐60 cells: association with enhanced fragmentation of mature DNA
64. Treatment of early breast cancer, vol. 1, Oxford, U. K. Oxford University Press. Early breast cancer trialist's collaborative group
65. Tamoxifen therapy in breast cancer control worldwide
66. Involvement of RP60C‐Src with two major signaling pathways in human breast cancer
67. Tamoxifen modulation of cis platin cytotoxicity in human malignancies
68. EGF induces tyrosine phosphorylation of phospholipase CII: a potential mechanism for EGF‐receptor signaling
69. Coexpression of platelet‐derived growth factor (PDGF) B chain and PDGF B‐type receptor in human gliomas
70. Epidermal growth factor as a target for therapy with anti‐receptor monoclonal antibodies
71. A derivative of staurosporine (CGP 41251) shows selectivity for PKC inhibition and in vitro antiproliferative and in vivo antitumor activity
72. High affinity VEGF binding and developmental expression suggest Flk‐1 as a major regulator of vasculogenesis and angiogenesis
73. Growth inhibited in vivo by a dominant negative Flk‐1 mutant
74. Phase II trial of suramin in patents with advanced renal cell carcinoma: Treatment results, pharmacokinetics and tumor growth‐factor expression
75. Therapeutic potential of chimeric and murine anti‐EGF receptor antibodies in a metastasis model for human melanoma
76. Prevention of lipopolysaccharide‐induced lethal toxicity by tyrosine kinase inhibitors
77. The tyrosine kinase inhibitor tyrphostin blocks the cellular action of nerve growth‐factor
78. Sphingosine‐1‐phosphate as second messenger in cell proliferation induced by PDGF an FCS mitogens
79. Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus
80. Selective inhibition of the EGF and Her‐2/Neu receptors by tyrphostins
81. Epidermal growth factor dependent activation of src family kinases
82. Activation of phospholipase C in human B cells is dependent on tyrosine phosphorylation
83. The use of immunotoxins for cancer therapy
84. The bryostatins
85. Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program
86. A phase I study of intravenous bryostatin1 in patients with advanced cancer
87. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator in Sos1
88. Tyrosine phosphorylation is an essential event in the stimulation of B lymphocytes by Staphylococcus aureus cowen I
89. The pathogenesis of atherosclerosis: perspective for the 1990's
90. Expression of platelet‐derived growth‐factor receptors is induced on connective tissue cells during chronic synovial inflammation
91. Chemistry and biology of immunophilins and their immunosuppressive ligands
92. Immunophilin sensitive protein phosphatase action in cell signaling pathways
93. The mechanism of action of cyclosporine A and FK 506
94. Successful treatment of murine melanoma with bryostatin 1
95. Residues crud for Ras interaction with GDP‐GTP exchangers
96. Dominant negative mutants of PDGF revert the transformed phenotype of human astrocytoma cells
97. Pathogenesis of pulmonary fibrosis in interstitial lung disease. Alveolar macrophage PDGF(B) gene activation and up‐regulation by interferon gamma
98. Monoclonal antibody therapy of human cancer: taking the Her2 proto‐oncogene to the clinic
99. Altered growth of human colon cancer cells disrupted at activated Ki‐ras
100. Cyclosporine, FK‐506 and rapamycin: pharmacological probes of lymphocyte signal‐transduction
101. Studies of the Her‐2/Neu proto‐oncogene in human breast and ovarian cancer
102. Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen
103. Cellular Ras Activity and tumor cell proliferation
104. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth
105. lyn
106. Inhibition of glioma cell growth by a truncated platelet‐derived growth factor‐β receptor
107. Expression of the epidermal growth‐factor receptor gene in human brain metastases
108. Activation of growth of murine tumor specific T‐cells which have in vivo activity with bryostatin 1
109. Expression of growth factor receptors in human brain tumors
110. Signal‐transduction by receptors with tyrosine kinase activity
111. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance
112. Workshop on suramin with emphasis on prostate cancer
113. Reversion of autocrine transformation by a dominant negative PDGF mutant
114. Recent research on the biological activity of suramin
115. A potent specific pure antiestrogen with clinical potential
116. Oncogenes, antioncogenes, and the molecular basis of multistep carcinogenesis
117. Bacterial lipopolysaccharide stimulates protein tyrosine phosphorylation in macrophages
118. Tyrosine kinase signal‐transduction in rheumatoid synovitis
119. Blocking of EGF‐dependent cell proliferation by EGF receptor kinase inhibitors
120. The antiproliferative effects of tyrosine kinase inhibitor tyrphostin on a human squamous cell carcinoma in vitro and in nude mice
121. Activation of phospholipase D by PDGF in rat C6 glioma cells: possible role in mitogenic signal‐transduction